Views & Analysis Unlocking the potential in rare disease research with decent... A survey by rare disease patient network Raremark found that 86% of the community members asked were interested in taking part in clinical trials.
Views & Analysis A collaborative approach to greater diversity in clinical tr... The need for diversity in clinical trial populations has been a topic of discussion across regulators and the industry in general for decades.
Views & Analysis Enabling new models of care: pursuing pharma’s partnership p... There is a huge, ongoing shift in how health and wellness is approached in the UK, and the changes will have important implications for NHS-industry partnerships.
Views & Analysis ‘No going back’ for clinical trials after COVID Trial sites have adapted swiftly to the restrictions of COVID-19, and patients have seen many knock-on benefits as a result.
Views & Analysis How patient insights are changing trial solutions Patients have been asking for patient-centric trial solutions for years – the industry just hasn’t been listening.
Views & Analysis True patient-focused research through decentralised and hybr... How can pharma improve the patient-centricity of its trials during COVID-19 and beyond?
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.